Trial Profile
Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Tiprelestat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- 26 Apr 2021 Status changed from active, no longer recruiting to completed.
- 23 Mar 2020 Planned End Date changed from 15 Mar 2020 to 1 Jul 2020.
- 23 Mar 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2020.